Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 939 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostate Cancer
Interventions
EPI-7386 (QD), EPI-7386 (BID), Abiraterone acetate, Apalutamide
Drug
Lead sponsor
ESSA Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Port Saint Lucie, Florida • Atlanta, Georgia • Boston, Massachusetts + 4 more
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Prostate Cancer, Recurrent Prostate Cancer
Interventions
Dasatinib
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Duarte, California • Loma Linda, California • Orange, California + 2 more
Conditions
Prostate Cancer
Interventions
docetaxel
Drug
Lead sponsor
Geriatric Oncology Consortium
Other
Eligibility
65 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions
Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Clinical Observation, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Interventions
saracatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Duarte, California
Conditions
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Interventions
BPX-601, Rimiducid
Biological · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 9 more
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
20
States / cities
Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 115 Years · Male only
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
BTP-114
Drug
Lead sponsor
Placon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more
Conditions
Metastatic Castration-Resistant Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
Interventions
XmAb®808, Keytruda® (pembrolizumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more
Conditions
Prostatic Neoplasms
Interventions
Not applicable for study
Other
Lead sponsor
Bayer
Industry
Eligibility
65 Years and older · Male only
Enrollment
2,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Waltham, Massachusetts
Conditions
Prostate Cancer
Interventions
Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
3
States / cities
Evanston, Illinois • New York, New York • Portland, Oregon
Conditions
Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Cancer Recurrent, Prostatic Cancer Metastatic
Interventions
Ga-68 PSMA-HBED-CC PET
Drug
Lead sponsor
Michael Graham PhD, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Prostate Cancer
Interventions
lapatinib ditosylate
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Raleigh, North Carolina
Conditions
Metastatic Prostate Cancer
Interventions
Enzalutamide, Niraparib
Drug
Lead sponsor
Paul Mathew, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ZEN003694, Enzalutamide
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Detroit, Michigan + 4 more
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Cirmtuzumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Conditions
Prostatic Neoplasms
Interventions
Cabozantinib, Docetaxel, Prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prostate Cancer
Interventions
Olaparib, AZD6738
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Charlottesville, Virginia
Conditions
Prostate Cancer
Interventions
Gefitinib plus etoposide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Hormone Refractory Prostate Cancer
Interventions
ADENOVIRUS/PSA VACCINE
Biological
Lead sponsor
David M Lubaroff
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa